Vaxart, Inc.
Business Overview: Vaxart, Inc. (OTCQX: VXRT)
Executive Summary
Vaxart is a clinical-stage biotechnology company focused on oral recombinant vaccines delivered as a room-temperature-stable tablet rather than an injection. Vaxart's proprietary VAAST platform uses a non-replicating adenovirus type 5 (Ad5) vector to deliver antigen-encoding DNA plus a dsRNA (TLR3 agonist) adjuvant to intestinal cells, aiming to generate mucosal, systemic, and T-cell immune responses without the needles, cold-chain logistics, or anti-vector-immunity limitations of many conventional vaccines. The company went public in 2018 via a reverse merger with Aviragen Therapeutics and now trades on the OTCQX after a prior Nasdaq delisting.
1. Core Business Model & How They Work
[ VAAST Platform: Ad5 Vector + DNA Antigen + dsRNA Adjuvant ]
➞ [ Enteric-Coated Tablet (room-temp stable) ] ➞ [ Oral Dosing, No Injection/Cold-Chain ]
➞ [ CRO-Run Trials + In-house Tableting (California) ] ➞ [ Partnership/Government Funding ]Vaxart relies heavily on third-party CROs and contract manufacturers for clinical trials, but keeps in-house bulk drug substance and tableting facilities in California — a hybrid model that preserves some manufacturing control over its core tablet technology while outsourcing trial execution.
2. Pipeline
| Program | Status | Notes |
|---|---|---|
| Norovirus (bivalent GI.1/GII.4) | Phase 1 (VXA-109, June 2025) | Higher NBAA titers with second-generation constructs; next stage contingent on partnership/funding; FDA requested new correlate-of-protection data |
| COVID-19 (XBB, KP.2 constructs) | Disrupted Phase 2b | BARDA-funded trial vs. mRNA comparator disrupted by stop-work orders; 10,000-participant cohort enrollment halted October 2025 |
| Seasonal influenza (trivalent tablet) | Phase 2 challenge study complete | H1N1 illness rates: 29% (vaccine) vs. 35% (commercial vaccine) vs. 48% (placebo) — directionally favorable but not statistically significant; preclinical avian H5N1 candidate also in development |
| HPV therapeutic (bivalent HPV-16/18) | Preclinical | Targets E6/E7 oncoproteins; regulatory filing needed before clinical trials |
| Antiviral royalties | Commercial (legacy) | Royalties from Relenza and Inavir; Vapendavir licensed to Altesa |
3. Competitive Landscape
| Indication | Named Competitors |
|---|---|
| Norovirus | Moderna and Merck (injectable programs), Cocrystal Pharma (oral antiviral), several Chinese developers |
| COVID-19 | Pfizer-BioNTech, Moderna, Novavax |
| Influenza | AstraZeneca, CSL, GSK, Sanofi, Pfizer, Merck; Inavir specifically faces Xofluza, Tamiflu, Rapiacta, and Relenza in Japan |
| HPV therapeutic | Inovio, Genexine |
4. Strategic Strengths & Risks
Strengths
- Validated viral vector: Ad5 has been used in over 200 clinical trials by other developers, which may reduce platform-level regulatory uncertainty.
- Differentiated delivery route: oral, room-temperature-stable tablets avoid cold-chain logistics and could enable repeat/booster dosing by sidestepping anti-vector immunity concerns that limit some injectable vector vaccines.
- Meaningful patent estate: three U.S. platform patents and over 25 foreign tablet-formulation patents.
- Non-dilutive government/foundation funding history: BARDA contract funding and a Bill & Melinda Gates Foundation grant for a breastfeeding norovirus study.
Risks
- Severe funding disruption: BARDA stop-work orders halted enrollment in Vaxart's largest trial (the 10,000-participant COVID-19 cohort) in October 2025, with available BARDA/ATI funding reduced to about $316.0 million after Modification No. 6 and a further reduction expected.
- Norovirus program now entirely dependent on finding a partner or outside funding to advance past Phase 1.
- Weak statistical results to date: the influenza Phase 2 challenge study showed directionally favorable but not statistically significant results versus a commercial comparator.
- Declining legacy royalty revenue: Inavir royalties are under pressure from Xofluza's market position and the 2024 patent expiry for laninamivir octanoate, opening generic competition.
- OTCQX listing (down from Nasdaq) and a small ~$102.7 million non-affiliate market value (June 30, 2025) reflect the company's diminished capital-markets standing.
- Competition from vastly better-resourced vaccine majors (Pfizer, Moderna, GSK, Sanofi, Merck, AstraZeneca) across every indication Vaxart pursues.
5. Financial Overview
| Metric | Figure | Strategic Context |
|---|---|---|
| BARDA/ATI available funding | ~$316.0 million (post-Modification No. 6, March 2026) | Further reduction expected; primary non-dilutive funding source now shrinking |
| 2024 BARDA award | $9.3 million (fully received) | Smaller, already-realized funding tranche |
| Non-affiliate market value | ~$102.7 million (June 30, 2025, at $0.45/share) | Reflects OTCQX-level capital markets standing |
| Cash position | Not disclosed in Item 1 excerpt | — |
6. Summary Conclusion
Vaxart has built a genuinely differentiated oral-tablet vaccine platform with real patent depth and a validated underlying viral vector, giving it technical credibility that smaller biotechs often lack. But the company's two most important programs — COVID-19 and norovirus — have both been set back in 2025, one by direct government funding disruption (BARDA stop-work orders) and the other by a now-mandatory search for a new financial partner, while legacy royalty income continues to erode. Vaxart's moat is real at the technology level (oral, cold-chain-free dosing) but currently undermined by funding instability that is largely outside the company's control.